NCT03565458View on ClinicalTrials.gov

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

PHASE1UnknownINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

April 5, 2018

Primary Completion Date

August 20, 2018

Study Completion Date

December 22, 2018

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Gemigliptin

zemiglo 50mg,LG Chem

DRUG

Dapagliflozin

forxiga, dapagliflozin 10mg

DRUG

Empagliflozin

jardiance 25mg, empagliflozin

Trial Locations (1)

07795

LG chem, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

LG Chem

INDUSTRY

NCT03565458 - Gemigliptin, Dapagliflozin, Empagliflozin DDI Study | Biotech Hunter | Biotech Hunter